Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas (Protocol 102)

This study is ongoing, but not recruiting participants.
Children's Hospital Boston
Children's Hospital of Philadelphia
Children's Research Institute
Children's Hospital Medical Center, Cincinnati
University of Chicago
University of Utah
Washington University School of Medicine
Information provided by (Responsible Party):
University of Alabama at Birmingham Identifier:
First received: February 20, 2008
Last updated: March 14, 2014
Last verified: February 2014
No Study Results Posted on for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: August 2014
  Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)